PMID- 26872013
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20161019
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 40
IP  - 5
DP  - 2016 May
TI  - Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of
      28 Cases.
PG  - 676-88
LID - 10.1097/PAS.0000000000000614 [doi]
AB  - Hepatosplenic T-cell lymphoma (HSTCL) is a rare type of lymphoma. Patients have a
      poor prognosis, and there is no standard of care. We evaluated 28 HSTCL patients 
      to determine factors that may be associated with outcome. There were 19 men and 9
      women with a median age of 32.5 years. Most patients had massive splenomegaly,
      and bone marrow showed sinusoidal involvement by lymphoma. The HSTCL cells
      expressed gammadelta T-cell receptor (TCR) in 20 (74%), alphabeta TCR in 5 (19%),
      and neither in 2 (7%) patients (1 case not assessed). Conventional cytogenetics
      and/or fluorescence in situ hybridization analysis in 24 patients at diagnosis
      showed isochromosome 7q (i7q) in 10 (42%) and trisomy 8 in 8 (33%) patients.
      Median overall survival (OS) and event-free survival (EFS) were each 28.3 months.
      Serum bilirubin level >/=1.5 mg/dL, alphabeta TCR expression, and trisomy 8 each 
      correlated significantly with shorter OS and EFS. Patients with HSTCL received a 
      variety of chemotherapy regimens with no regimen better than any other. However, 
      patients who underwent stem cell transplant showed longer survival (OS: hazard
      ratio 0.3, P=0.09; EFS: hazard ratio 0.2, P=0.034). In conclusion, although HSTCL
      patients have a poor prognosis overall, the data presented support the novel
      suggestions that HSTCL patients can be stratified into 2 prognostic groups, with 
      an elevated serum bilirubin level, alphabeta TCR expression, and trisomy 8
      identifying a poorer prognostic group. In addition, the outcomes of this patient 
      cohort suggest that stem cell transplantation has value for the treatment of
      patients with HSTCL.
FAU - Yabe, Mariko
AU  - Yabe M
AD  - Departments of *Hematopathology daggerStem Cell Transplantation section
      signLymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston,
      TX #Biostatistics **Translational and Molecular Pathology, The University of
      Texas MD Anderson Cancer Center, Houston paragraph signDepartment of Pathology,
      UT Southwestern Medical Center, Dallas, TX double daggerDepartment of Pathology
      and Cell Biology, Columbia University Medical Center, New York, NY
      parallelDepartment of Pathology, University of Miami, Miami, FL.
FAU - Medeiros, L Jeffrey
AU  - Medeiros LJ
FAU - Tang, Guilin
AU  - Tang G
FAU - Wang, Sa A
AU  - Wang SA
FAU - Ahmed, Sairah
AU  - Ahmed S
FAU - Nieto, Yago
AU  - Nieto Y
FAU - Hu, Shimin
AU  - Hu S
FAU - Bhagat, Govind
AU  - Bhagat G
FAU - Oki, Yasuhiro
AU  - Oki Y
FAU - Patel, Keyur P
AU  - Patel KP
FAU - Routbort, Mark
AU  - Routbort M
FAU - Luthra, Rajyalakshmi
AU  - Luthra R
FAU - Fanale, Michelle A
AU  - Fanale MA
FAU - Bueso-Ramos, Carlos E
AU  - Bueso-Ramos CE
FAU - Jorgensen, Jeffrey L
AU  - Jorgensen JL
FAU - Vega, Francisco
AU  - Vega F
FAU - Chen, Weina
AU  - Chen W
FAU - Hoehn, Daniela
AU  - Hoehn D
FAU - Konoplev, Sergej
AU  - Konoplev S
FAU - Milton, Denai R
AU  - Milton DR
FAU - Wistuba, Ignacio
AU  - Wistuba I
FAU - Li, Shaoying
AU  - Li S
FAU - You, M James
AU  - You MJ
FAU - Young, Ken H
AU  - Young KH
FAU - Miranda, Roberto N
AU  - Miranda RN
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
RN  - Chromosome 8, trisomy
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Bone Marrow/pathology
MH  - Bone Marrow Examination
MH  - Child
MH  - Child, Preschool
MH  - Chromosomes, Human, Pair 7
MH  - Chromosomes, Human, Pair 8/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Hepatomegaly/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Isochromosomes
MH  - Kaplan-Meier Estimate
MH  - *Liver Neoplasms/drug therapy/genetics/immunology/mortality/pathology
MH  - *Lymphoma, T-Cell/drug therapy/genetics/immunology/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Proportional Hazards Models
MH  - Receptors, Antigen, T-Cell, alpha-beta/genetics/immunology
MH  - Receptors, Antigen, T-Cell, gamma-delta/genetics/immunology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Splenic Neoplasms/drug therapy/genetics/immunology/mortality/pathology
MH  - Splenomegaly/pathology
MH  - Therapeutics
MH  - Time Factors
MH  - Trisomy/genetics
MH  - United States
MH  - Young Adult
EDAT- 2016/02/13 06:00
MHDA- 2016/08/30 06:00
CRDT- 2016/02/13 06:00
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1097/PAS.0000000000000614 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2016 May;40(5):676-88. doi: 10.1097/PAS.0000000000000614.